/PRNewswire/ Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation.
Share this article
Share this article
MENLO PARK, Calif., Jan. 7, 2021 /PRNewswire/ Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor. Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the company s scientific advisory board (SAB).
Ablacon plans to use the new funds to advance the company s product portfolio and continue expanding patient access to the CE Marked Ablamap® system. Dr. Haines will join the rest of the Ablacon all-star SAB to work with the company to map out a clinical research strategy to methodically demonstrate the promise of using Electrographic Flow and Ablamap to improve patient care in atrial fibrillation (AF).